HMGB1 and primary cutaneous T-cell non-Hodgkin lymphoma: Notably, Fredholm S. et al. proved that 72% of CTCL patients had pY-STAT3-positive malignant T cells, and staining for eosinophils and the trafficking factor HMGB1 was also positive, which supports HMGB1 as a possible therapeutic target [134].